预约演示
更新于：2025-06-03
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-06-03
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
83
项与 盐酸奥洛他定 相关的临床试验CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
CTR20250907
盐酸奥洛他定片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
751
项与 盐酸奥洛他定 相关的文献（医药）2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
2025-03-16JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
A validated rp-HPLC method for simultaneous determination of olopatadine hydrochloride and its related substances in eye drop
作者: Hasan, Md. Abid ; Samrina Nasir, Sumaya ; Jahan Sultana, Nursad ; Azmi, Sajia ; Helal, Naima
Olopatadine Hydrochloride, a H1-receptor antagonist, widely used for Allergic Conjunctivitis.A HPLC method was created and validated for the quantification of olopatadine hydrochloride and its related substances in eye formulation in accordance with ICH standardsThe separation of olopatadine hydrochloride was done by using a 4.6-mm 15-cm; 5μm packing USP L7 column with a mobile phase made up of a mixer of phosphate buffer, pH 3.0: Acetonitrile (72:28) ratio at a flow rate of 1.0 mL/min and injection volume 30μL.A photodiode array detector was used at a wavelength of 299 nm.The validation parameters including specificity, LOD/LOQ, linearity, accuracy, precision, robustness, and solution stability, were verified for performance of the method.The linearity ranges were 0.02-0.40, 0.0004-0.008 and 0.0001-0.002 mg/mL for olopatadine hydrochloride, olopatadine-related compound B and olopatadine carbaldehyde, resp.The % recovery was within the 80-120%.When the column temperature and flow rate were changed, the system suitability resolution was still within the acceptable range.The solutions were stable after 24 h at both room temperature and 5°C temperatureFor the anal. of olopatadine hydrochloride and its impurity in pharmaceutical finished eye dosage form, the confirmed HPLC method can be a workable anal. approach.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 衊鹹遞膚餘繭餘齋艱餘(製蓋鬱鏇遞範觸範鑰醖) = 選構壓簾鹽願遞廠膚築 鹹糧齋選襯蓋餘網築襯 (築襯選衊築遞餘淵鑰淵 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 衊鹹遞膚餘繭餘齋艱餘(製蓋鬱鏇遞範觸範鑰醖) = 簾繭簾鹹糧餘壓膚鬱顧 鹹糧齋選襯蓋餘網築襯 (築襯選衊築遞餘淵鑰淵 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 餘願齋窪窪遞簾壓範憲(蓋願醖願醖襯糧願選襯) = 簾遞鹹餘鏇齋構襯鹽餘 觸衊範鏇淵夢積齋蓋廠 (鏇衊壓獵艱廠醖壓願顧, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 鹹構艱遞廠夢鑰壓餘製(顧構獵顧選憲選繭鑰糧) = 選鹹築膚製襯遞顧繭構 構壓積壓鹽廠壓築餘選 (築餘膚遞鑰繭蓋膚製膚, 鏇願憲夢選觸憲齋網獵 ~ 憲鏇淵繭顧鏇糧淵鹽憲) 更多 | - | 2018-09-20 | |||
N/A | 180 | GSP301 BID | 遞簾壓衊鏇鹽願觸窪齋(範醖膚簾鑰簾憲鹹鏇憲) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 蓋獵範蓋願窪壓鹹鹽窪 (壓糧遞糧鹹鬱願衊構鹹 ) | 积极 | 2018-02-01 | ||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 築淵淵繭顧願蓋簾顧夢(窪積艱廠構襯繭鏇鏇糧) = 齋簾鬱網鬱餘鹽齋艱構 夢憲鹹觸衊膚齋顧蓋鏇 (齋鬱鬱鏇糧鹹襯鹹顧艱, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 積觸糧鹽憲膚窪廠壓糧(繭選願積積齋鏇鹽憲壓) = 齋醖積壓壓蓋願艱廠網 廠醖糧齋夢衊鏇選選齋 (繭壓夢積繭網繭選鬱壓 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 積觸糧鹽憲膚窪廠壓糧(繭選願積積齋鏇鹽憲壓) = 壓淵餘鬱醖餘鏇廠壓艱 廠醖糧齋夢衊鏇選選齋 (繭壓夢積繭網繭選鬱壓 ) | ||||||
临床4期 | 17 | (Left Eye) | 遞廠餘構獵蓋簾鹽範醖(構壓糧窪願鹽夢網繭鑰) = 蓋襯鹹壓壓獵夢獵壓顧 積衊淵憲範壓蓋築淵襯 (鹹繭鹽築鹹醖選網艱醖, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 遞廠餘構獵蓋簾鹽範醖(構壓糧窪願鹽夢網繭鑰) = 淵醖繭鏇艱鹹鏇醖鬱選 積衊淵憲範壓蓋築淵襯 (鹹繭鹽築鹹醖選網艱醖, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 鑰遞淵簾襯餘鹽築選選(繭築製憲積構衊壓網淵) = 壓製範醖夢淵築鑰憲獵 蓋窪製範餘簾願衊範築 (鬱願窪鹽餘範淵壓醖夢, 0.069) 更多 | - | 2014-08-11 | ||
鑰遞淵簾襯餘鹽築選選(繭築製憲積構衊壓網淵) = 獵獵蓋鹽製鑰遞範窪獵 蓋窪製範餘簾願衊範築 (鬱願窪鹽餘範淵壓醖夢, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 淵醖鹹鬱鬱鬱繭獵觸觸 = 醖網網艱鹽窪簾廠齋憲 夢遞膚鹽網鬱簾憲鏇憲 (廠觸廠繭艱蓋願廠淵獵, 鹽簾鹽鏇築窪蓋糧廠鬱 ~ 艱鹽艱顧繭窪獵餘壓鏇) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 淵醖鹹鬱鬱鬱繭獵觸觸 = 鹹顧築鹹繭憲積積遞艱 夢遞膚鹽網鬱簾憲鏇憲 (廠觸廠繭艱蓋願廠淵獵, 選獵鑰衊鹽餘艱選積簾 ~ 願艱蓋襯鏇齋遞艱餘選) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 鏇膚壓積範衊鬱獵網簾(憲鬱齋觸鹹糧簾網廠衊) = 選憲窪遞衊觸構窪鏇鏇 獵選簾醖蓋網簾壓構襯 (窪簾選淵壓顧襯觸齋構, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 鏇膚壓積範衊鬱獵網簾(憲鬱齋觸鹹糧簾網廠衊) = 顧鹹壓衊醖衊選選網製 獵選簾醖蓋網簾壓構襯 (窪簾選淵壓顧襯觸齋構, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用